Lifecore Biomedical (NASDAQ:LFCR) stock is off 10% year to date, but hedge funds remain convinced that this company has a bright future. One estimate suggests hedge funds own 45% of Lifecore’s shares, with the top seven shareholders owning 54% of the company.
However, one fund said it had all but exited the stock during the third quarter on concerns about timing, while another fund warned that the bull thesis will take time to play out. The question now is just how long investors have to wait.
Read hedge fund letters here
Background on Lifecore Biomedical
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) that scales drugs from concept to commercialization. The company does...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
